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Abstract
Background: Brief intervention programs are clinically beneficial, and cost efficient treatments for low back pain, when
offered at 8-12 weeks, compared with treatment as usual. However, about 30% of the patients do not return to work.
The European Guidelines for treatment of chronic low back pain recommends Cognitive Behavioral Therapy (CBT), but
conclude that further research is needed to evaluate the effectiveness of CBT for chronic low back pain.
Methods/Design: The aim of the multicenter CINS trial (Cognitive Interventions and Nutritional Supplements) is to
compare the effectiveness of 4 different interventions; Brief Intervention, Brief Intervention and CBT, Brief
Intervention and nutritional supplements of seal oil, and Brief Intervention and nutritional supplements of soy oil.
All participants will be randomly assigned to the interventions. The nutritional supplements will be tested in a
double blind design. 400 patients will be recruited from a population of chronic low back pain patients that have
been sick listed for 2-10 months. Four outpatient clinics, located in different parts of Norway, will participate in
recruitment and treatment of the patients.
The Brief Intervention is a one session cognitive, clinical examination program based on a non-injury model, where return
to normal activity and work is the main goal, and is followed by two booster sessions. The CBT is a tailored treatment
involving 7 sessions, following a detailed manual. The nutritional supplements consist of a dosage of 10 grams of either
soy or seal oil (capsules) per day for 3 months, administered in a double blind design. All patients will be followed up with
questionnaires after 3, 6 and 12 months, while sick leave data will be collected up to at least 24 months after
randomization. The primary outcome of the study is sick leave and will be based on register data from the National
Insurance Administration. Secondary outcomes include self-reported data on disability, pain, and psychological variables.
Conclusions: To our knowledge, the CINS trial will be the largest, randomized trial of psychological and nutritional
interventions for chronic low back pain patients to date. It will provide important information regarding the
effectiveness of CBT and seal oil for chronic low back pain patients.
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Background
Muscle pain including low back pain (LBP) is common
in the general population, and accounts for about 50%
of the long-term sick leave in Norway. It is also among
the most common reasons for frequent visits to the gen-
eral practitioner [1]. Lack of knowledge related to the
understanding of pain mechanisms, treatment strategies
and management of back pain contribute to the pro-
blem [2]. The transition from normal complaints to pro-
longed illness and disability is poorly understood, but
there are new studies suggesting augmented central pain
processing [3]. This transition has recently been attribu-
ted to neurobiological and psychobiological sensitization
mechanisms [4]. The theoretical and empirical back-
ground for this hypothesis has been developed in some
detail. The main foundation is a general and systematic
stress theory, the Cognitive Activation Theory of Stress,
(CATS), developed from empirical data from human
and animal studies [5].
The treatment principles for LBP and for other types
of non-specific muscle pain, have changed over the last
15 to 20 years, from traditional treatments like bed rest
and inactivity to more active treatment strategies ("The
back pain revolution”)[6]. Brief intervention programs
have been demonstrated to be clinically beneficial and
cost effective [7]. The prognosis for patients with
chronic low back pain (CLBP) is poor when the condi-
tion has lasted over an extended period of time [8,9].
Non-specific pain with high levels of comorbidity
For most patients with LBP, a precise pathoanatomical
diagnosis is often impossible due to weak associations
between symptoms and anatomical findings [10]. A high
degree of comorbidity has been described in patients
with non-specific LBP [11]. In a survey of 457 patients
referred to a spine clinic, less than 2% of the patient
population reported LBP as their only complaint [12]. A
substantial proportion of the patients reported a signifi-
cant number of other subjective health complaints,
including widespread muscle pain as well [12]. This is
consistent with previous Danish and Norwegian data
[13,14] and recent findings in the US [11]. In these stu-
dies, high levels of comorbidity were associated with a
poor prognosis. Comorbidity seems to be a general phe-
nomenon in patient groups with unspecific conditions
and subjective health complaints, or “medically unex-
plained symptoms” such as irritable bowel syndrome
[15]. The high number of different subjective health
complaints in these conditions and reports of the effec-
tiveness of psychological treatments, such as CBT in
several of these patient groups [16-18], suggest that
there are common psychobiological elements and less
specificity than the diagnostic labels suggest [3].
Theories of chronic pain
It is well recognized that the relationship between
pathology and impairment are influenced by psychoso-
cial variables. CLBP is therefore often viewed as a biop-
sychosocial phenomenon, where biological,
psychological and social factors interact and mutually
influence each other [19]. Avoidance may be an adaptive
response to acute pain. However, sustained avoidance of
movement, social interactions, leisure activities, and
work, may increase pain and disability [20]. A number
of models have evolved over the years to explain chronic
pain behavior. These include the Gate Control Theory
of Pain [21], operant conditioning paradigms [22], fear
avoidance models [20,23,24], and acceptance models
[25,26]. All of these models are brought together within
the Cognitive Activation Theory of Stress (CATS) [5],
which assumes that acquired response and stimulus
expectancies determine the physiological and psycholo-
gical responses, which in turn influence subjective health
complaints such as pain through neurobiological sensiti-
zation [4,5].
Evidence based treatments for LBP
The treatment principles applied in this study follow the
evidence-based guidelines for the treatment of CLBP,
developed in Europe (http://www.backpaineurope.org)
[27]. The recommended treatments include conservative
treatments like CBT, supervised exercise therapy, brief
educational interventions (BI), and multidisciplinary bio-
psychosocial treatments. A recent review of psychologi-
cal treatments for CLBP, provide support for the efficacy
of psychological interventions, including CBT, among
persons with CLBP [28]. While the evidence points to
BI and CBT as effective treatments, many of the studies
included in the review, are at risk of bias because of
methodological problems, and it has been argued that
confidence in the results are unwarranted [29]. BI’s are
associated with positive outcomes for return to work
early in the process [30]. However, it is still unclear
whether the effect would be as beneficial later on, when
the patients may develop behavior that adversely affects
their illness and recovery. Some studies have shown that
Reme et al. BMC Musculoskeletal Disorders 2011, 12:152
http://www.biomedcentral.com/1471-2474/12/152
Page 2 of 12
CBT is effective in reducing pain, while other studies
have shown beneficial effects on physical and mental
function and sick leave rates, but not pain [31,32]. It is
difficult to replicate studies and results of the effects of
CBT, because the components of the therapy and the
experience of the therapists vary, and the treatment pro-
tocols are rarely documented. The European Guidelines
for treatment of chronic low back pain emphasize the
need to evaluate the effectiveness of using CBT-thera-
pists without formal training in clinical psychology.
These issues will be addressed and answered in the cur-
rent trial; the CBT treatment protocol will be documen-
ted in a manual, and the treatment will be monitored
closely. Therapists with different professional back-
grounds will be recruited, trained, and followed in order
to apply the protocol.
Nutritional supplements
Seal oil is a marine oil that is relatively rich in the
omega-3 polyunsaturated fatty acids eicosapentaenoic
acid (EPA; 20:5n-3), docosapentaenoic acid (DPA;
22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). It is
promoted commercially for its allegedly, beneficial
effects on joint and muscle pain. There is little scientific
documentation of the effect of seal oil, apart from an
indication of a positive effect on muscle pain in a few
Norwegian studies [33-36] of patients with inflammatory
bowel disease and psoriatic arthritis. There are no clini-
cal trials of the effectiveness of seal oil on patients with
low back pain or unspecific musculoskeletal complaints
as their main problem.
Pain and the immune system have many signal sub-
stances in common. Potentially algogenic substances are
released from immune cells into inflamed tissues, i.e.
cytokines from mast cells or TNFa from macrophages.
Antagonism or neutralization of TNFa reduces pain and
hyperalgesia in many animal models of inflammation.
TNFa antibodies or neutralizing agents have been a suc-
cessful therapy for pain relief in many autoimmune disor-
ders such as arthritis, psoriasis, ankylosing spondylitis,
and Crohn’s disease [37]. Dietary fatty acids are incorpo-
rated into cell membranes of blood and tissues, where
arachidonic acid (AA; 20:4n-6) generally prevails as a
result of the Western diet where its precursor linoleic
acid (18:2n-6) is in grand supply [38]. AA and the n-3
PUFA EPA, DPA and DHA, found mainly in fatty fish
and marine oils, are substrates for various pro- and anti-
inflammatory lipid mediators respectively [38]. Eicosa-
noids are a group of hormone-like compounds involved
in both pro-inflammatory and anti-inflammatory pro-
cesses and suppression of the immune system. As a gen-
eral rule, eicosanoids derived from arachidonic acid (AA)
are more potent triggers of immunological responses
than eicosanoids derived from eicosapentaenoic acid
(EPA, 20:5n-3) [38], though recently AA has been shown
to have anti-inflammatory effects as well as the above n-3
PUFAs [38,39]. Soy oil is a vegetable oil rich in LA. It
also contains some a-linolenic acid (18:3n-3), which is
the precursor of EPA, but direct intake of marine oils,
fish or other seafood is generally necessary because the
conversion of a-linolenic acid to EPA and DHAis limited
[40]. Lowering the ratio of n-6 to n-3 PUFAs to suppress
n-6 eicosanoids and proinflammatory cytokines, may be
important for pain relief in chronic inflammatory disor-
ders since western diet is dominated by linoleic acid and
AA [41].
Cortisol
Cortisol is accepted as a robust marker of activation of
adrenocortical activity (HPA activity) and follows a 24
hour rhythm with low levels in the evening and a char-
acteristic peak level, usually found the first hour after
awakening [42,43]. Short-term activation of the system
is necessary and adaptive. Sustained activation of the
system occurs when the individual does not expect to
cope with a situation, and may be associated with nega-
tive health outcomes [5]. A flat cortisol curve, with a
low deviation from morning to evening and high eve-
ning values may be an indication of insufficient recovery
or sustained activation [44]. High levels of cortisol in
the evening have been found in patients with chronic
widespread pain [45] and chronic fatigue syndrome [46].
In one recent study, maladaptive coping strategies were
negatively correlated to the cortisol response after awa-
kening in CLBP patients [47].
Predictors of outcome
A number of different factors contribute to the treat-
ment success of interventions for LBP. The most impor-
tant factors seems to be subjective ratings of pain
intensity and disability, affective parameters, pain related
cognitions, health control beliefs, and coping strategies
[2,48-51]. More objective parameters, like medical data
and objective work-related factors, appear less important
in predicting treatment outcome [48,52]. It appears that
subjective evaluations of health status and job satisfac-
tion are more important predictors of the patients’ like-
lihood of returning to work after sick leave, than the
physical aspects of disability and job demands [53]. One
of the strongest predictors of return to work seems to
be the patients’ own belief in return to work [51,54-57].
Methods/Design
Aims
The main goal in this study is to test out if a systematic
CBT or nutritional supplements have additional effects
on Brief Intervention (BI) in patients sick listed between
2 and 10 months for unspecific LBP. The patients will
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be randomized to BI only, BI and CBT, BI and seal oil,
or BI and soy oil (Figure 1).
Objectives
The CINS trial is designed to answer the following
questions:
Primary objectives
1) Are BI and CBT, and/or BI and seal oil, more
effective than BI alone (BI and placebo) in increasing
return to work, reducing health complaints, or both?
2) Are BI and CBT more effective than BI and seal
oil, in increasing return to work, reducing health
complaints, or both?
Secondary objectives
The secondary analyses are exploratory, but will be
guided by previous findings.
1) What are the relative cost-effectiveness and cost-
benefit of these interventions?
2) What is the prevalence of psychiatric disorders in
this population of chronic LBP patients?
3) What baseline factors predict different treatment
outcomes in the different intervention groups?
4) Will any of the interventions impact the cortisol
profiles of the LBP patients?
Hypotheses of efficacy
1) BI and CBT will be superior in return to work
and reduction of sick leave
2) BI and seal oil will reduce health complaints, but
will not influence return to work or sick leave
Number and source of participants
The goal is to recruit 400 participants (age between 20
and 60 years) to the trial (see sample size calculations).
The Norwegian National Insurance Administration
(NAV) will send a letter of invitation to patients that
have been at least 50% sick listed, for 2 to 10 months
due to LBP. In Norway, at any point in time, there are
approximately 14000 patients on sick leave for 6
months, due to low back pain (Brage, NAV, personal
communication). Patients on sick leave that geographi-
cally belong to one of the participating clinics are
invited to participate in the study. The letters of invita-
tion will be sent from NAV, and will include informa-
tion about the study, and a response sheet. If a patient
is interested in participating in the study, he or she fills
out their contact information on the response sheet, and
returns it to the research unit (Uni Health). After the
response sheet has been received, the patients will be
invited to the participating local back pain/pain clinic
for a final evaluation for inclusion into the study. For
those included, baseline assessment, BI, and randomiza-
tion to any of the four interventions will be performed.
Duration
Treatment according to randomization starts as soon as
possible after allocation, with a maximum of 2 weeks
delay. The main outcome assessment will be one year
after randomization, but data on sick leave and other
social benefits will be followed for at least another year.
Inclusion criteria
1) Sick leave due to LBP for 2-10 months
2) At least 50% sickness compensation
3) Both participant and clinician agree that randomi-
zation is acceptable
4) Written informed consent from the participant
5) At least 50% employed
6) One of the following ICPC diagnoses: L02, L03,
L84, or L86
7) Age between 20 and 60 years
Exclusion criteria
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Figure 1 Flowchart of trial design.
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4) Osteoporosis (known osteoporotic fracture, or on
anti osteoporostic medication)
5) Currently being treated for cancer
6) Recent back trauma
7) Serious psychiatric disorders (mainly due to
ongoing psychosis, high suicide risk, and/or serious
depression), assumed to be incompatible with parti-
cipation in the trial.
8) Not fluent in Norwegian (assumed to be incom-
patible with CBT)
9) Debilitating Cardiovascular disease
10) Patients on warfarin treatment (blood thinner, e.
g. Marevan)
11) Ongoing insurance trial, lawsuit, or pending legal
action for LBP or related conditions
Baseline assessment
At the clinic, the patients will be informed of their
rights according to the Helsinki declaration, receive
additional information about the study, and sign a writ-
ten informed consent form before any trial related pro-
cedure takes place. The design of the trial will be
explained to the patients in detail; e.g. with emphasis on
the potential advantages of randomization, a description
of each active intervention, consequences of participa-
tion, potential side effects of any of the treatments, and
the necessity of the blinded nutritional supplement pro-
cedure. Then the patients will fill out the questionnaires,
and a blood sample will be drawn to determine the
baseline level of fatty acid profile in a selection of the
participants. All patients will receive the Brief Interven-
tion (BI), consisting of a clinical examination by a medi-
cal doctor (MD), and follow-up by a physiotherapist.
During the clinical examination the MD will screen the
patients according to the selection criteria. The MDs
will also screen for psychiatric pathology, and exclude
patients with serious psychopathology assumed to be
incompatible with participation in the trial. The Mini-
International Neuropsychiatric Interview (M.I.N.I) [58]
will be used for this screening. After the patients have
received the BI treatment, all eligible patients will be
randomized to one of four treatment groups.
Randomization
The patients will be randomized, using concealed rando-
mization, to one of the following four treatments; 1) BI
only, 2) BI and CBT, 3) BI and seal oil, or 4) BI and soy
oil. This is done according to a computer generated ran-
domization list, generated by the trial statistician. The
list is stratified by clinic and gender. A central telephone
randomization system, as already set up by our research
unit will be used. At each of the participating clinics, a
research assistant that is not involved in the treatment
calls the research unit (Uni Health) to get information
on which treatment the patient is randomized to. The
research unit receives information about the patient’s id
number, gender, age, and diagnoses before the treatment
allocation is disclosed, ensuring that the sequence is
concealed until the intervention is assigned. The alloca-
tion code, including details of block size etc. will not be
revealed to the researchers or the clinicians until
recruitment, data collection, and laboratory analyses are
complete. For those patients allocated to nutritional
supplementation, the clinics provide blinded boxes, con-
taining capsules with either seal oil or soy oil. All
researchers, clinicians, and participants are blinded to
treatment allocation of individual participants for the
nutritional supplementation. Researchers at Uni Health,
the trial statistician, and those assessing the main out-
come of the study will be blinded to group assignment.
Patients and CBT clinicians will not be blinded to group
assignment.
Ethical considerations
The Norwegian Regional Ethical Committee and the
Norwegian Social Science Data Services have approved
the study. The research will be carried out in compli-
ance with the Helsinki declaration. Personal confidenti-
ality is guaranteed, and declarations of voluntary
participation with detailed information on the study
processes and purposes, will be signed by each partici-
pant, emphasizing the right to withdraw from the
experiment at any time without any explanation. We
find the randomization procedure ethically acceptable
because BI has been shown to be effective, and all
patients will receive that treatment. However, the effect
of BI together with a prolonged and systematic CBT for
this patient group has not been studied. This study has
a more systematic and consistent theoretical foundation,
including a systematic manual for the therapy, than pre-
vious studies. Previous studies on BI have been per-
formed in patients at an earlier stage of LBP. The
treatment with seal oil and soy oil is beneficial or inert,
but there are no RCTs on the possible effect in patients
with LBP. The evidence of effect of seal oil is sufficiently
demonstrated to do the experiment, and the oil is
already in use in other controlled pilot trials.
Treatment interventions
1. BI (Brief intervention)
BI is a one session cognitive, clinical examination pro-
gram based on a non-injury model, where return to nor-
mal activity and work is the main goal. Previous studies
of BI for LBP have shown significant reduction of sick
leave compared to treatment as usual [7,30,59-61]. A
treatment manual for the BI is written. Consensus
between all participating BI-clinicians was reached about
Reme et al. BMC Musculoskeletal Disorders 2011, 12:152
http://www.biomedcentral.com/1471-2474/12/152
Page 5 of 12
the final version of the treatment manual. The essential
feature of the intervention is the use of an eclectic cog-
nitive and educational approach, throughout a thorough
medical examination, conducted by a specialist in physi-
cal medicine and rehabilitation. The intervention
includes diagnostic clarification, reassurance about nor-
mal findings, and encouragement to engage in physical
activity as normal as possible. BI was checked against
the Cognitive Therapy Adherence and Competence
Scale (CTACS) [62], and according to CTACS it can
not be categorized as a full-scale CBT. Patients will be
guided towards a new understanding of the back pain,
and given practical advice about how their back function
may be improved. The examination is thorough, with
detailed feedback on any medical findings and normal
functions, and clear and consistent explanations on pain
and defense mechanisms. If any “red flags” are identi-
fied, indicating serious pathology, the patients will be
referred appropriately and excluded from the study.
Neurological examinations will be conducted, and infor-
mation regarding the importance of the findings will be
given (e.g. positive comments about normal findings
such as normal nerve function in legs). Painful muscles
will be identified. If the patient moves in a tense way,
attention is given to make the patient aware of how
muscles may become dysfunctional, and how this may
be maintained, and possibly worsen the condition. If the
patient brings medical images, these are demonstrated
and explained. Patients are told that looking for the
source of pain on radiographs have limited importance;
degenerative changes in the spine are most often normal
aging processes and not necessarily painful. They are
informed about the good prognosis, and the importance
of staying active to avoid development of muscle dys-
function. They are further reassured that light activity
will not be harmful to their backs, but on the contrary,
light activity is more likely to improve their condition.
The main purpose of the intervention is to provide the
patients with coping skills to manage their back pain
through evidence based information, practical advice
and reassurance, and to motivate and encourage them
to stay active, despite the pain. All personnel involved
with the patients will give them the same consistent
message. After the medical examination, the patients
will receive a follow-up session with a physiotherapist,
involving an educational and a behavioral part. The pur-
pose of the education is to strengthen the message given
in the medical examination. The purpose of the beha-
vioral component is to help the patient turn the new
insight into practical action. Patients will be encouraged
to contact the spine clinic whenever they want. They
will also receive two booster sessions to ensure that they
still have the insight and understanding of their condi-
tion, and that they are able to cope with it. The first
booster is given within 2 weeks, while the other is given
6 months after the first BI session. The booster sessions
will last about 10-15 minutes. The results from the
examination will be sent to the patients’ primary care
physician.
2. BI and CBT
Seven sessions of individual CBT, over a period of 2-3
months, will be given in addition to the BI. The CBT
builds on the message contained in the BI, and is theo-
retically based on Chalder’s CBT model for CFS patients
[17], and on the Cognitive Activation Theory of Stress
(CATS) [5]. This CBT model assumes that cognitive,
emotional, physiological, and behavioral responses are
linked, and that changes in one of these areas will result
in changes in others. During the treatment, patients are
helped to change their interpretation of the pain and
associated fear, symptom focusing, and avoidance. Parti-
cipants are encouraged to see complaints as temporary
and reversible, and not as signs of harm, or as evidence
of a permanent condition or as a fixed disease pathol-
ogy. The aim of the intervention is to help patients
change cognitive- and behavioral factors assumed to be
partly responsible for the maintenance of symptoms and
disability. Return to work is an outlined goal of the
treatment.
A treatment manual has been written by Reme &
Chalder [63], and developed in close collaboration with
experienced specialists in family medicine, psychiatry,
and physical medicine and rehabilitation, all educated in
cognitive behavioral therapy (Egil Fors, Tone Tangen,
Peer Staff and Jens Ivar Brox). LBP patients seem to be
sensitive to conflicting messages. Even small changes in
the information given, may bring back the fear and
avoidance behavior [64]. This requires both a detailed
manual, and consistent training and supervision of the
clinicians. The CBT-clinicians in this study are all health
care personnel with varied backgrounds; six MD’s with a
specialty in physical medicine and rehabilitation, two
psychologists, one psychiatric nurse, and one phy-
siotherapist. All had to undergo a general CBT-course
(with a minimum duration of 10 days and 15 hours of
group supervision), or be familiar with CBT from pre-
vious education and training. In addition, all CBT-clini-
cians received three days of training in this LBP-tailored
CBT, followed by at least one individual session with a
patient not included in the study. The session is
recorded on videotape, and rated by the supervisors and
the first author of the treatment manual (SER). The ses-
sion will be rated according to protocol adherence, and
satisfying quality of the CBT. All clinicians have to be
approved before treating patients included in the trial.
All CBT sessions in the trial will be audio taped. Tapes
will be used for supervision as well as rating for research
purposes. Supervision is offered approximately every 4th
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month, but the clinicians are offered phone and email
contact with supervisors when needed. A random selec-
tion of the tapes are continuously evaluated by indepen-
dent raters (SER and graduate students in psychology),
with a percentage evaluated twice for inter rater reliabil-
ity, using a modified Norwegian version of the Cognitive
Therapy Adherence and Competence Scale [65].
3. Nutritional supplements (seal oil and soy oil)
Findings from patients with inflammatory bowel disease
(IBD) suggest that seal oil may reduce musculoskeletal
pain. IBD patients report high levels of comorbidity,
including musculoskeletal pain [66]. A substantial ameli-
oration of joint pain after short-term administration of
seal oil, has been reported in one pilot study [35], and
one controlled study [36]. In Bjørkkjær et al. [67] pros-
taglandin E2 (PGE2) levels were also reduced. Given
these findings, testing a possible effect of seal oil in LBP
patients seems a reasonable next step, and an ethically
acceptable experiment. In addition, with the current
interest in alternative medicine in the Norwegian popu-
lation, seal oil seems to have high face validity as a
potential effective supplement for muscle pain.
Patients randomized to nutritional supplements, will
receive commercially available seal oil for the same
duration as the CBT treatment, in a double-blind rando-
mized, controlled design. Oils will be administered as 20
capsules daily, providing 638 mg EPA, 399 mg DPA,
and 798 mg DHA per day for those receiving seal oil,
and 5.31 g linoleic acid (18:2n-6) per day for those
receiving soy oil. Before meals, 10 capsules should be
taken in the morning and 10 capsules in the evening,
with fluid. Capsules will be stored at room temperature
in blinded light-protected boxes during the study. Cap-
sules are chosen because they are easy to administrate,
have no taste, less regurgitation problems, and are easier
to blind, compared to using the oils in liquid form.
Testing of the oils before the intervention showed that
vitamin A, i.e. sum retinol (13-, 11-, 9-cis) and all trans
retinol, i.e. A1 and 3,4 didehydro-all-trans retinol (A2) in
both oils were below 0.28 mg/kg. Vitamin D3 content in
daily soy oil and seal oil dosages were 1 μg and 0 μg
respectively. The antioxidant D-alpha-tocopherol was
added in the case of seal oil, giving a vitamin E (alpha-
tocopherol) content in seal oil and soy oil of 85.4 and
16.6 g/100 g respectively. The seal oil contains 56.6 g/
100 g monounsaturated fatty acids, which are less prone
to lipid peroxidation than polyunsaturated fatty acids
(PUFAs), and the oil has no known major adverse
effects [35,36]. Soy oil is common in the diet in the wes-
tern world, and is considered a placebo in this trial.
Cholesterol levels in seal oil and soy oil were 36.8 and
2.9 g/100 g respectively. The seal oil is a refined oil
from the blubber of adult harp seals (Phagophilus groen-
landicus). The soy oil is a refined oil from soybeans,
which are GMO-free. Both oils were approved according
to current legislations on contaminants and relevant
quality standards
Drop out from randomized treatment
Participants who drop out of treatment will be asked if
they are willing to continue filling out questionnaires.
Those who wish to continue contributing data to the
study, but who are not able to or decline to come to the
clinic, will receive the questionnaires by mail, together
with pre-paid return envelopes.
Assessment and Procedures
All participants will fill out questionnaires at the clinic
immediately before BI. Follow up is conducted at 3, 6,
and 12 months after the first session of BI. Data on sick
leave will be obtained from the Norwegian National
Insurance Administration (see outcome), and will also
be collected 24 months after randomization (Figure 1).
Measures
Primary outcome measures
The main outcome in the study is sick leave. The data
on sick leave/insurance status will be based on register
data from the Norwegian National Insurance
Administration.
Secondary outcome measures
Questionnaires Standard forms contain items for demo-
graphics, medication, previous treatments, pain intensity,
and life style variables. Below follows a short description
of the most important questionnaires, all validated and
in Norwegian:
1. Subjective Health Complaints (SHC): The SHC-
inventory records complaints without asking for
attributions or medical diagnosis [68]. The selection
of items is not based on any specific theory, but cov-
ers the most frequent health complaints and reasons
for being seen by a general practitioner [69]. The
inventory has 5 subscales; musculoskeletal, pseudo-
neurological, gastrointestinal, flu, and allergy com-
plaints, and covers the period of the previous 30
days. The reliability and validity are good [68].
2. Illness Perception Questionnaire Revised (IPQ-R):
This scale has five subscales providing information on
the five components underlying the cognitive repre-
sentation of the illness. These are: identity (the symp-
toms that the patient associates with the illness), cause
(personal ideas about etiology), timeline (the perceived
duration of the illness), consequences (expected effects
and outcome) and cure-control (how one controls or
recovers from the illness). The internal consistency,
validity, and test-retest reliability of the separate scales
have been found to be good [70].
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3. Oswestry Disability Index [71] and Norwegian
Function Assessment Scale [72] both assesses func-
tional limitation. Reliability and validity of the
Oswestry Disability Index have been found to be
good [73]. The Norwegian Function Assessment
Scale has 7 sub domains, and reliability and validity
have been tested and found good [74].
4. Hospital Anxiety and Depression Scale (HAD) and
Hopkins Symptom Checklist (HSCL) both assesses
mood. The HAD scale has been found to be a reli-
able instrument for detecting states of depression
and anxiety, and the anxiety and depressive subscales
are also valid measures of severity of the emotional
disorder [75]. The scale avoids overlap with somatic
symptoms of physical illness. The HSCL-25 scale
consists of 25 questions about the presence and
intensity of the most common symptoms of anxiety
and depression [76].
5. Chalder Fatigue Scale: This is an 11-item scale
measuring physical and mental fatigue. The sum
score can range from 0 to 33; a bimodal score ran-
ging from 0-11 can also be obtained. The fatigue
scale has been used extensively in research and has
good psychometric proprieties [77]. It has also been
validated in Norwegian [78].
6. Fear Avoidance Beliefs Questionnaire (FABQ):
This is a scale that measures self-reported fear
avoidance thoughts and beliefs in LBP patients [79].
It has 2 subscales; fear avoidance for physical activity
and fear avoidance for work. Reliability and validity
was tested in a Norwegian population of LBP
patients and found to be acceptable [80].
7. Pain Stages of Change Questionnaire (PSOCQ):
This is a scale measuring motivation to change. It is
a multidimensional instrument designed to measure
readiness to change in individuals with chronic pain
[81]. Five stable subgroups have been identified and
named: Pre-contemplation, contemplation, non-con-
templative action, participation, and the ambivalent
subgroup [82].
8. A mini-version self-administrated food frequency
questionnaire (FFQ) has been developed, with focus
on habitual intake (i.e. last year) of fish and other
seafood for dinner, as sandwich spread, in salads or
as snack. The questions relate to type of seafood,
frequency of intake and in some cases portion size.
It also includes questions about the use of long
chain omega-3 PUFA supplements (fish oil, seal oil
etc.).
Psychiatric Interview The Mini-International Neurop-
sychiatric Interview (MINI) was applied as the struc-
tured diagnostic interview [58] for DSM-IV [83] and
ICD-10 [84] assessing psychiatric disorders. It is a short
structured diagnostic interview, developed jointly by
psychiatrists and clinicians in the United States and Eur-
ope. It is based on “yes” and “no” answers and covers 23
Axis 1 disorders. In the multiaxial system of DSM-IV,
Axis I disorders include all major mental disorders as
well as developmental and learning disorders. The MINI
interview usually takes 15-20 minutes, and has high
reliability and validity [58]. We used the Norwegian ver-
sion of MINI Plus [85].
Blood samples
For a selected number of participants, fasting venous
blood samples are drawn and stored in -80°C freezer for
later analysis, or in a -20°C freezer for 4 weeks, before
subsequent rapid analysis. The samples will be taken
before and after the interventions, using validated meth-
ods at the NIFES [86] with modifications. Fatty acid
composition will be measured in unwashed erythrocytes,
to get information on compliance, and possible corro-
boration to any treatment effect. Extra vials of unwashed
erythrocytes and plasma at inclusion and after 3 months
will be stored in a bio bank for a possible future
balanced risk assessment (nutrients and contaminants in
same sample) of seafood intake.
Saliva samples
Previous studies have shown that cortisol measured
through saliva using salivette, is a reliable and valid
measure of unbound and free cortisol level in plasma
[87]. Saliva cortisol will be measured in order to assess
the cortisol day curve (stress profile). Furthermore, the
aim is to investigate if the different treatments affect the
cortisol profile. The participants collect saliva on two
consecutive days between Tuesday and Friday at base-
line and 3 months later. Four saliva samples will be col-
lected each day; immediately after awakening, 30
minutes later, and at 3 pm and 10 pm. Participants will
be asked to avoid food, drinks and nicotine 30 minutes
before collecting saliva, and keep a written record of the
exact time of awakening and saliva collecting. The parti-
cipants keep the saliva samples in their freezer at home,
before bringing them to the laboratory for analyses.
Analyses
Sample size calculations
The sample size calculations were based on data from
Hagen et al. [30] and the transition probabilities calcu-
lated for the intervention group in that study. The sam-
ple size was based on the transition probabilities at 9
months, where approximately 40% of the individuals
had returned to work. Hagen et al. [59] found that the
effects were largest for the earlier period after the inter-
vention. This is therefore an argument to use 40% off
sick leave at 9 months as the most relevant measure for
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effect in this study. This was compared to a hypothe-
sized 60% return to work (RR 1.5) as an adequate effect
size. The sample size calculations were based on stan-
dard formulas for calculating sample size, for studies
comparing binomial proportions using the statistical
package “R” (Library Hmisc). This may increase the
power of the estimates in the analyses, since the simpler
method used for the calculation does not include in this
issue. All calculations were based on a power of 80%
and a significance level of 5%.
Separate sample size calculations for males and
females were computed. The total number of individuals
should be approximately N = 4*n, where n is the calcu-
lated sample size and 4 is the number of arms in the
study. The total number of males should be N = 4*65 =
260 and the total number of females N = 4*81 = 324. If
we control for gender in the analysis instead of perform-
ing stratified analyses, we do not need to calculate sepa-
rate sample sizes for men and women. The total
number of participants should be 97 in each arm (N =
388). These numbers require a multi-centre design.
Analysis strategy
Primary analyses of efficacy
Sick leave/insurance status will be calculated as risks of
shifting between different states of sick leave, disability
pension, and recovered. The outcome from the partici-
pating clinics will be combined if no gross center effect
is found. The analyses will follow the “intention to
treat” principle. Per protocol analysis will also be per-
formed. The proportions of participants with a positive
primary outcome will also be compared across the treat-
ment groups. If there are significant differences, we will
estimate the number of participants that need to be
treated in order for one additional participant to benefit
(NNT), compared to the least effective therapy. A Cox-
proportional hazards model may model the transitions
between the different states. Regression models for the
transition probabilities will also be performed. Explana-
tory variables (treatment) and confounders (e.g. age,
gender) will be included as in any regression model.
Possible changes in diagnosis and other characteristics
will be built in. Partial recovery represented by partial
sick leave will be accounted for.
Secondary analyses of efficacy
Any significant effects of any of the interventions will be
estimated by a standard cost benefit formula [88-90], as
used by Hagen et al [59]. Benefits will be measured in
terms of increases in the net present social value of pro-
duction, when intervention causes a reduction in the
number of days on sick leave. This is calculated as the
product of the treatment effect, i.e. the reduction in sick
leave days, and the productivity gains for the society
when a person works instead of receiving benefits. For
each person the social value of production is based on
mean earnings at inclusion in the treatment group. Cost
of treatment also includes follow-up at the clinics.
Potential differences in treatment costs between the
groups, which are related to treatments received inde-
pendent of the study, will be accounted for by follow-up
questionnaires from the participants.
We will also evaluate health complaints/pain and dis-
ability as recorded by the questionnaires at 3, 6 and 12
months. Appropriate regression models, based on the
distribution for the different outcomes, will be per-
formed, including variables found to be statistically sig-
nificant predictions.
Predictions and process of treatment
Associations between post-treatment outcomes and pre-
dictor variables will be examined, using multiple linear
and logistic regression modeling techniques.
Independent overseers
The independent Scientific Advisory Board, and the
Trial Steering Committee, provides supervision for the
trial and safeguards its integrity, including data monitor-
ing and possible ethical challenges. In addition, The
Regional Ethical Committee and the Norwegian Social
Science Data Services have approved the study.
Confidentiality
All data collected is regarded as confidential and
securely stored in paper-formats, and on memory sticks.
The memory sticks and all data containing personal
information are stored in a fireproof safe.
Therapists’ compliance with treatment manuals
Following and checking audio recordings will monitor
therapist compliance with treatment manuals. Any sig-
nificant deviations from the manual will be noted and
feedback given to the therapist. Therapists are allowed
to treat trial participants once they have been approved
as competent. Every fifth BI and CBT session will be
randomly chosen and evaluated independently by an
assessor to assess adherence to the manual.
Discussion
To our knowledge, the CINS trial will be the largest
randomized trial where brief intervention and cognitive
behavioral therapy are compared to nutritional interven-
tions for LBP. It will provide important information
about effectiveness of the targeted interventions, possi-
ble adverse effects, cost-effectiveness, prevalence, predic-
tors, and mechanisms of change. The results will
provide significant information to patients, health care
providers and commissioners about which treatment
works for whom.
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